Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma-Reference-Cited by-同舟云学术

Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma

Published:2023-01 Issue: Volume:17 Page:100214
ISSN:2590-1702
Container-title:Clinical Infection in Practice
language:en
Short-container-title:Clinical Infection in Practice

Author:

Goldwater Marissa-Skye,Stampfer Samuel D.,Sean Regidor Bernard,Bujarski Sean,Jew Scott,Chen Haiming,Xu Ning,Kim Clara,Kim Susanna,Berenson James R.^ORCID

Funder

Institute for Myeloma and Bone Cancer Research

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference50 articles.

1. Agha ME, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: A need for vigilance in the postmasking era. Open Forum Infectious Diseases 2021;8. doi:10.1093/ofid/ofab353.

2. Vaccination in multiple myeloma: Review of current literature;Alemu;Clin. Lymphoma Myeloma Leuk.,2016

3. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant;Andrews;N. Engl. J. Med.,2022

4. Humoral response rate and predictors of response to BNT162b2 mRNA COVID-19 vaccine in patients with multiple myeloma;Avivi;Br. J. Haematol.,2021

5. Elotuzumab enhances the Th2-mediated immune response of dendritic cell induced by immunomodulatory drugs (IMiDs);Azuma;Blood,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma;Oncotarget;2024-02-05

2. Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma;Haematologica;2024-01-25

3. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry;Hematological Oncology;2023-12-04

4. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN);Leukemia;2023-05-04